Newly Aligned Teams Sped US FDA’s Drug Quality Reviews Over Pandemic Hurdles
Realignment played key role in keeping assessments on track as COVID-19 buckled pharmaceutical supply and distribution chains and prevented inspections.
You may also be interested in...
US FDA excludes chronic care products from list of medicines bolstered by domestic production investment and federal procurement requirements.
The Trump administration’s move to strengthen domestic manufacture of essential medicines raises a lot of questions – and industry’s ire.
A fresh executive order from US president Joe Biden calls for short-term and long-term study, broad consultation, and co-ordination with allies on the domestic supply chain.